A Phase III, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT07043400

Study #:
STUDY00161991

Start Date:
Jan 08, 2026

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT07043400

View Complete Trial Details & Eligibility at ClinicalTrials.gov